U.S. lawmakers ramp up scrutiny of FDA following agency’s approval of controversial Alzheimer’s drug
By
Alicia Lasek
Sep 07, 2021
The FDA is being asked to help explain how Aduhelm (aducanumab) met accelerated approval criteria when so many experts — including internal advisers — have flagged insufficient safety and efficacy...
How to beat the COVID-19 staffing crisis? Communication, strong oversight
By
Liza Berger
Sep 25, 2020
The pandemic has hammered long-term care on numerous operational fronts, from testing the field’s infection control capabilities to depressing occupancy rates. One of the hardest-hit areas has been staffing.